EUCTR2013-000601-23-DE进行中（未招募）不适用
A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Fluvirin®) in Healthy Adults - Fluvirin
ovartis Vaccines and Diagnostics S.r.l.0 个研究点开始时间: 2013年3月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to participate in this study, a subject must meet ALL of the following inclusion criteria:
- •- Is a male or female volunteer ages 18 years or older, mentally competent, willing and able to give written informed consent prior to study entry;
- •- Is able to comply with all the study requirements; and
- •- Is in good health as determined by the outcome of medical history, physical examination, and clinical judgment of the investigator
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 63
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 63
排除标准
- •In order to participate in this study, a subject must not meet any of the following exclusion criteria:
- •?Has behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject’s ability to participate in the study;
- •?Has a serious chronic or acute disease (in the judgment of the investigator) including, but not limited to
- •-medically significant cancer (except for benign or localized skin cancer, cancer in remission for =10 years, or localized prostate cancer that has been clinically stable for >2 years without treatment)
- •-medically significant advanced congestive heart failure (ie, New York Heart Association [NYHA] class III and IV)
- •-chronic obstructive pulmonary disease (ie, Global initiative for chronic Obstructive Lung Disease [GOLD] stage III and IV)
- •-autoimmune disease (including rheumatoid arthritis and excepting Hashimoto’s thyroiditis that has been clinically stable for =5 years)
- •-diabetes mellitus type I
- •-poorly controlled diabetes mellitus type II
- •-advanced arteriosclerotic disease
- •-history of underlying medical condition such as major congenital abnormalities requiring surgery, chronic treatment, or associated with developmental delay (eg, Down’s syndrome)
- •-acute or progressive hepatic disease
- •-acute or progressive renal disease
- •-severe neurological (especially Guillain–Barré syndrome) or psychiatric disorder
- •-severe asthma
- •?Has a history of any anaphylactic reaction and/or serious allergic reaction to any component of the study vaccine (see section 5.1);
- •?Has a known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from:
- •-receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study,
- •-receipt of immunostimulants within the past 6 months,
- •-receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivates within the past 3 months and for the full length of the study, or
- •-suspected or known human immunodeficiency virus (HIV) infection or HIV related disease
- •?Has known or suspected drug or alcohol abuse within the past 2 years;
- •?Has bleeding diathesis or conditions associated with prolonged bleeding time that, in the investigator’s opinion, would interfere with the safety of the subject;
- •?Is not able to comprehend and to follow all required study procedures for the whole period of the study;
- •?Has a history or any illness that, in the opinion of the investigator, would pose additional risk to the subjects because of participation in the study;
- •?Has the following within the past 6 months:
- •-had any laboratory confirmed seasonal or pandemic influenza disease
- •-received any seasonal or pandemic influenza vaccine
- •?Has received any other vaccine within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine during the study;
- •?Has acute or chronic infections requiring antiviral therapy within the last 7 days;
- •?Has experienced fever (ie, body temperature [preferably oral] =38.0°C) within the last 3 days of intended study vaccination;
- •?Has been participating in any clinical trial with another investigational product 4 weeks prior to first study visit or intends to participate in another clinical study at any time during the conduct of
研究者
相似试验
进行中（未招募）
不适用
Seasonal Optaflu trial 2013/14MedDRA version: 14.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsInfluenzaEUCTR2013-000621-30-DEovartis Vaccines and Diagnostics GmbH
进行中（未招募）
1 期
A Phase 3 study of Tafasitamab plus Lenalidomide in patients withRelapsed or Refractory Diffuse Large B-Cell Lymphoma.Diffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: LLTClassification code 10012883Term: Diffuse lymphomaSystem Organ Class: 100000004864EUCTR2021-006049-36-NOIncyte Corporation81
进行中（未招募）
1 期
A Phase 3 study of Tafasitamab plus Lenalidomide in patients withRelapsed or Refractory Diffuse Large B-Cell Lymphoma.EUCTR2021-006049-36-DKIncyte Corporation81
进行中（未招募）
1 期
A Phase 3 study of Tafasitamab plus Lenalidomide in patients withRelapsed or Refractory Diffuse Large B-Cell Lymphoma.Diffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: LLTClassification code 10012883Term: Diffuse lymphomaSystem Organ Class: 100000004864EUCTR2021-006049-36-FIIncyte Corporation81
进行中（未招募）
1 期
A Phase 3 study of Tafasitamab plus Lenalidomide in patients withRelapsed or Refractory Diffuse Large B-Cell Lymphoma.Diffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: LLTClassification code 10012883Term: Diffuse lymphomaSystem Organ Class: 100000004864EUCTR2021-006049-36-CZIncyte Corporation81